Reltecimod

N/A

Report date: 2024/10/18 20:00:35
NME

Base Information

Drug NameReltecimod
Drug Alias Name瑞替莫德ReltecimodumP2-TAAB-103
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 inhibitors
TargetsT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsAcute Kidney InjuryFasciitis, NecrotizingSoft Tissue Infections +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAtox Bio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAtox Bio Ltd
Active IndicationsN/A
Inactive IndicationsAcute Kidney InjuryFasciitis, NecrotizingSoft Tissue Infections +[5] 

Other Information

ATC CodeN/A
Related LinksN/A